Excitement and investment in the microbiome and its near-term opportunities for the biopharma industry are rapidly increasing. As the microbiome is implicated in progressively more diseases, emerging studies have validated the concept of microbiome-based diagnostics and therapeutics. The accelerating pace of scientific and technologic advances makes it especially challenging for industry leaders to keep up with the latest developments, and understand their scientific and strategic implications. "The Microbiome: Emerging Opportunities for Biopharma" is designed to address this gap.
Led by Ramnik Xavier, MD, PhD, and other renowned Harvard Medical School faculty, participants will complete the program with a framework to guide their thinking about how to evaluate microbiome programs, identify emerging areas of opportunity and set strategic priorities for research, discovery and investment.
Download program brochure
Complete the form below to download brochure and to receive more information about the program as it is announced, including additional details about the curriculum, faculty and participant mix.
About the Faculty Director:
Ramnik Xavier, MD, PhD, is the Kurt Isselbacher Professor of Medicine at Harvard Medical School. He is also a Core Institute Member and Co-Director of the Infectious Disease and Microbiome Program at the Broad Institute of MIT and Harvard; Director of the Center for Computational and Integrative Biology at Massachusetts General Hospital; and Co-Director of the Center for Microbiome Informatics and Therapeutics at MIT.